Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CVTX - CV Therapeutics, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: idos who wrote (266)	8/1/2006 5:40:48 PM
From: dr.praveen	Read Replies (1) \| Respond to of 411

Hi idos, Sorry I missed your post somehow. Cardiologists are a bunch of people who move very slowly on new drugs. There is not much of a compelling reason for them to reco the costlier Ranexa before the MERLIN results early next year. I heard a few of them are reco to use Ranexa with Viagra since other nitrates are contraindicated :-) I also like Regadenoson in their portfolio and looking to see more data from CVT 6883 in Asthma like today. But their primary driver is MERLIN results and Regadenoson phase III results(I think it is Q4 06). Todays news on CVT 6883: Message 22676991 An interesting story on Ranexa: phillyburbs.com Regards, Praveen PS: I don't have a position in CVTX.